Search clinical trials for: Q702

Total 20 results

Qurient Co., Ltd.

Recruiting

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

Solid Tumor | Metastatic Cancer | Advanced Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

AML | MDS

China
J2H Biotech

Recruiting

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

Non-alcoholic Steatohepatitis

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Advanced Solid Tumor

China
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg

Hypertension

Korea, Republic of
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Rheumatoid Arthritis

Poland, Croatia, Russian Federation, Bulgaria, Czech Republic, Former Serbia and Montenegro, Slovakia, Slovenia, Ukraine
Chong Kun Dang Pharmaceutical

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy

Essential Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy

Essential Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical
Samsung Medical Center; Asan Medical Center; Seoul National University Hospital

Recruiting

The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy (CKD-702)

Non-Small Cell Lung Cancer

Korea, Republic of
Pierre Fabre Medicament

Completed

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors (OCEANI)

Melanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLC

China
Qurient Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Hepatocellular Cancer

Korea, Republic of, United States
Cancer Research UK
Teon Therapeutics, Inc.

Recruiting

TT-702 in Patients With Advanced Solid Tumours. (CURATE)

Advanced Solid Tumors

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Rheumatoid Arthritis

Bulgaria, Croatia, Former Serbia and Montenegro, Poland, Russian Federation, Slovenia
Nissan Chemical Industries

Completed

Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

Intermittent Claudication | Peripheral Vascular Disease

United States
Pierre Fabre Medicament

Active, not recruiting

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (OCEANII)

Non-Small Cell Lung Cancer

China, Taiwan
National Cancer Center, Korea

Recruiting

CKD-702 Plus Irinotecan in Gastric Cancer

Gastric Cancer

Korea, Republic of
Pfizer
Eli Lilly and Company; Merck Sharp & Dohme LLC; Merck KGaA, Darmstadt, Germany

Recruiting

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)

Metastatic Colorectal Cancer

United States, Denmark, Spain, Australia, France, Italy, Belgium, Slovakia, Canada, Czechia, Germany, Netherlands, Norway, Poland, Sweden, United Kingdom
Pierre Fabre Medicament
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (NAUTICALCRC)

Metastatic Colorectal Cancer | BRAF V600E

China
National Institute of Allergy and Infectious Diseases...
Duke University; National Institutes of Health (NIH); Department of Health and... and other collaborators

Not yet recruiting

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

HIV

United States, South Africa
Pfizer
Eli Lilly and Company; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co....

Recruiting

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Neoplasms

Canada, United States, Taiwan, Belgium, Korea, Republic of, Australia, China, Spain, New Zealand, Japan, Denmark, Germany, Netherlands, Italy, Russian Federation, Finland, Bulgaria, Czechia, India, Mexico, Slovakia, South Africa, Uk... and more

Search clinical trials for: Q702

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations